

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders.

In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

March 11, 2026

To Shareholders,

Company Name: Renascience Inc.
Representative: Toshio Miyata, Chairman and CEO
(Code: 4889 TSE Growth)
For inquiries, please contact Administration Dept.

Notice of Revision of Full-Year Earnings Forecasts for the Fiscal Year Ending March, 2026

We hereby announce that, at a meeting of the Board of Directors held on 3/11/2026, we have resolved to revise our full-year financial forecasts for the fiscal year ending March 2026 (April 1, 2025 - March 31, 2026), which were announced on November 12, 2025, as follows:

Particulars

1. Revisions to the forecast of financial results for the current fiscal year (April 1, 2025 to March 31, 2026)

	Operating revenue	Operating profit	Ordinary income	Net income for the year	Net income for the year (Per share)
Previous forecast (A)	Millions of yen 133	Millions of yen △380	Millions of yen △343	Millions of yen △345	Yen Sen △27.18
Revised forecast (B)	95	△425	△386	△387	△30.09
Increase (Decrease) (B-A)	△38	△45	△42	△41	
Increase (Decrease) (%)	△28.7	—	—	—	
(Reference) Results for the previous period (Fiscal year ended March, 2025)	132	△178	△178	113	8.92

2. Reason for revision

Due to delay in the start of a phase II clinical trial for male pattern baldness and age-related alopecia at Eirion Therapeutics, Inc. in the United States, the company will be unable to record milestone income (US\$200,000). In addition, due to lower than expected cost for a phase III clinical trial for malignant melanoma, subsidy income from the National Institutes of Biomedical Innovation, Health and Nutrition will decrease by approximately 9 million yen, resulting in a decrease in operating revenue. As a result, the company has revised its full-year earnings forecast.

*The above forecast is based on judgments and assumptions made in light of information available as of the publication date of this document. Actual results may differ from these forecasts due to various future factors.